UroGen Pharma(URGN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 • New Drug Application for UGN-102 accepted by US FDA; PDUFA target action date set for June 13, 2025 • JELMYTO® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023 • $254.2 million in cash, cash equivalents and marketable securities as of September 30, 2024 • Conference call and webcast to be held today at 10:00 AM ET PRI ...